Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yihe Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms, Drug Resistance, Neoplasm, Receptors, Androgen. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
The mechanism of endocrine resistance in breast cancer (BC) extends beyond ESR1 mutations to include compensatory androgen receptor (AR) signaling. However, current therapeutic agents directed at the AR ligand-binding pocket (LBP) face the risk of failure due to mutations within this pocket. Herein, we reported a series of PROTACs targeting the AR coactivator binding site (AR-CBS) to overcome endocrine resistance in AR+ BC. Among which, degrader 18o could not only effectively degrade AR, but also potently inhibit the proliferation of MCF-7 and multiple mutant or resistant BC cells. Simultaneously, 18o effectively blocked estrogen receptor α (ERα) signaling through a dual mechanism involving ERα protein downregulation and suppression of its transcriptional activity. Importantly, 18o exhibited excellent antitumor activity in both MCF-7 and LCC2 xenografted models. This proof-of-concept study confirms that AR-CBS is a promising target for BC treatment and highlights degrader 18o as a potential candidate for overcoming the endocrine resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medi…
- Frontier Science Center for Immunology and Metabolism, State Key Laboratory of Virology and Biosafety, Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Dr…
ORCID-Profile: Xin Han, Hai-Bing Zhou
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Wu, Y., Xie, B., Liang, J., Wei, D., Wang, Y., Yin, Y., Deng, X., Wang, C., Ni, J., Yang, L., Dong, C., Han, X., & Zhou, H. B. (2025). Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01926
Vancouver
Wu Y, Xie B, Liang J, Wei D, Wang Y, Yin Y, et al. Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01926
BibTeX
@article{Wu2025,
author = {Wu, Yihe and Xie, Baohua and Liang, Jinsen and Wei, Dongmei and Wang, Yubo and Yin, Yudong and Deng, Xiaofei and Wang, Chao and Ni, Jian and Yang, Lanxin and Dong, Chune and Han, Xin and Zhou, Hai-Bing},
title = {Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01926}
}
EUVIMED